In addition, CAR T cells have been engineered to target the mesothelin antigen and secrete PD-L1 blocking antibody to remove the immunosuppressive effect of tumor on CAR T cells (termed Sec-MesoCAR-T cells) thereby increasing the therapeutic effect of CAR T cells on pancreatic cancer (169). The gene discussed is CD274; the disease is pancreatic neoplasm.